Baseline characteristics and preoperative medications
| Patients without AF (n=266) | Patients with AF (n=103) | P value | |
| Age (years) | 60.8±10.0 | 67.8±9.5 | <0.001 |
| Male | 200 (75%) | 80 (77%) | 0.617 |
| BMI (kg/m2) | 28.4 (16.7–53.6) | 28.4 (16.7–53.6) | 0.520 |
| Gensini score | 59.8 (6–172) | 63.7 (16–142) | 0.264 |
| Hypertension | 160 (60%) | 67 (65%) | 0.386 |
| Hyperlipidemia | 61 (22%) | 24 (23%) | 0.940 |
| Diabetes mellitus | 121 (45%) | 41 (40%) | 0.324 |
| Smokers | 137 (51%) | 52 (50%) | 0.861 |
| PAD | 15 (6%) | 4 (4%) | 0.489 |
| PCI | 43 (16%) | 20 (19%) | 0.456 |
| COPD | 28 (%10) | 17 (%16) | 0.115 |
| HATCH score | 1.20 (0–6) | 1.50 (0–6) | 0.017 |
| Previous medications | |||
| Beta-blocker | 219 (82%) | 84 (81%) | 0.861 |
| ACEi | 88 (33%) | 39 (38%) | 0.386 |
| ARB | 45 (17%) | 15 (15%) | 0.582 |
| CCB | 33 (12%) | 20 (19%) | 0.078 |
| Statin | 137 (52%) | 59 (57%) | 0.335 |
| Furosemide | 15 (6%) | 12 (12%) | 0.047 |
| Spironolactone | 11 (4%) | 5 (5%) | 0.761 |
Data are presented as n (%) or mean±SD.
ACEi, ACE inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BMI, body mass index; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; PAD, peripheral arterial disease; PCI, percutaneous coronary intervention.